Edward Arrowsmith

1.9k total citations
60 papers, 1.2k citations indexed

About

Edward Arrowsmith is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Edward Arrowsmith has authored 60 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Edward Arrowsmith's work include Renal cell carcinoma treatment (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Multiple Myeloma Research and Treatments (11 papers). Edward Arrowsmith is often cited by papers focused on Renal cell carcinoma treatment (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Multiple Myeloma Research and Treatments (11 papers). Edward Arrowsmith collaborates with scholars based in United States, United Kingdom and Germany. Edward Arrowsmith's co-authors include John D. Hainsworth, Jeffrey R. Infante, Howard A. Burris, Johanna C. Bendell, Joseph R. Mace, Scott S. Tykodi, David R. Spigel, Lowell L. Hart, Ian W. Flinn and Ralph V. Boccia and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Edward Arrowsmith

56 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward Arrowsmith United States	18	623	544	536	234	148	60	1.2k
Lorenzo D’Ambrosio Italy	18	590 0.9×	337 0.6×	777 1.4×	173 0.7×	151 1.0×	50	1.2k
Yu-Nien Sun United States	10	566 0.9×	528 1.0×	332 0.6×	196 0.8×	64 0.4×	12	1.4k
Arturo Loaiza‐Bonilla United States	13	523 0.8×	287 0.5×	238 0.4×	262 1.1×	64 0.4×	62	960
Chin‐Tung Chen United States	12	574 0.9×	387 0.7×	259 0.5×	152 0.6×	98 0.7×	24	988
Haiyi Guo China	12	743 1.2×	350 0.6×	429 0.8×	144 0.6×	116 0.8×	28	1.3k
Martin Poleski United States	12	548 0.9×	357 0.7×	192 0.4×	193 0.8×	170 1.1×	18	1.2k
Bum Jun Kim South Korea	18	536 0.9×	337 0.6×	449 0.8×	168 0.7×	85 0.6×	60	1.1k
Naoki Takahashi Japan	17	841 1.3×	515 0.9×	435 0.8×	349 1.5×	150 1.0×	89	1.6k
Dana S. Thompson United States	21	1.0k 1.6×	507 0.9×	442 0.8×	151 0.6×	67 0.5×	75	1.5k
Émpar Mayordomo Spain	12	428 0.7×	277 0.5×	264 0.5×	153 0.7×	91 0.6×	16	829

Countries citing papers authored by Edward Arrowsmith

Since Specialization

Citations

This map shows the geographic impact of Edward Arrowsmith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Arrowsmith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Arrowsmith more than expected).

Fields of papers citing papers by Edward Arrowsmith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Arrowsmith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Arrowsmith. The network helps show where Edward Arrowsmith may publish in the future.

Co-authorship network of co-authors of Edward Arrowsmith

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Arrowsmith. A scholar is included among the top collaborators of Edward Arrowsmith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Arrowsmith. Edward Arrowsmith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2025). Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 549–549.

Wang, Judy S., Edward Arrowsmith, J. Thaddeus Beck, et al.. (2025). Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors. Investigational New Drugs. 43(4). 894–903. 1 indexed citations

Choueiri, Toni K., Jaime R. Merchan, Robert A. Figlin, et al.. (2025). Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. The Lancet Oncology. 26(1). 64–73. 4 indexed citations

Falchook, Gerald S., James A. Reeves, Sunil Gandhi, et al.. (2024). A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. Cancer Immunology Immunotherapy. 73(4). 72–72. 8 indexed citations

Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2023). LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 34. S1328–S1329. 9 indexed citations

Abrams, Joseph Y., et al.. (2023). Provider messaging for precision treatment (ProMPT): A notification pilot study to inform actionable genomic findings.. JCO Oncology Practice. 19(11_suppl). 448–448. 1 indexed citations

Choueiri, Toni K., David F. McDermott, Jaime R. Merchan, et al.. (2023). Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. The Lancet Oncology. 24(5). 553–562. 64 indexed citations

Lim, Emerson A., James A. Reeves, David R. Spigel, et al.. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1182–S1183. 3 indexed citations

Berdeja, Jesús G., Tara Gregory, Edward A. Faber, et al.. (2021). A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort. American Journal of Hematology. 96(4). 428–435. 13 indexed citations

10.

Herbst, Roy S., Johanna C. Bendell, Edward Arrowsmith, et al.. (2020). Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology. 16(2). 289–298. 44 indexed citations

11.

McFarlane, Joshua J., Mark D. Kochenderfer, Mark R. Olsen, et al.. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer. 18(6). 469–476.e4. 29 indexed citations

12.

Hainsworth, John D., James A. Reeves, Joseph R. Mace, et al.. (2016). A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Targeted Oncology. 11(5). 643–653. 54 indexed citations

13.

Yoon, Harry H., Johanna C. Bendell, Fadi S. Braiteh, et al.. (2016). Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Annals of Oncology. 27(12). 2196–2203. 98 indexed citations

14.

Hart, Lowell L., Joseph R. Mace, Edward Arrowsmith, et al.. (2015). Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 100(5). 670–676. 79 indexed citations

15.

Hainsworth, John D., et al.. (2013). High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Genitourinary Cancer. 11(3). 283–289.e1. 5 indexed citations

16.

Berdeja, Jesús G., Michael R. Savona, Joseph R. Mace, et al.. (2013). A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM). Blood. 122(21). 1937–1937. 8 indexed citations

17.

Yardley, Denise A., Howard A. Burris, Bobby L. Clark, et al.. (2011). Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Breast Cancer. 11(3). 146–152. 24 indexed citations

18.

Hainsworth, John D., Jeffrey R. Infante, David R. Spigel, et al.. (2011). A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma. Cancer Investigation. 29(7). 451–455. 76 indexed citations

19.

Spigel, David R., F. Anthony Greco, Howard A. Burris, et al.. (2011). A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer. 12(3). 187–191. 9 indexed citations

20.

Arrowsmith, Edward, William R. Macon, Marsha C. Kinney, et al.. (2002). Peripheral T-cell Lymphomas: Clinical Features and Prognostic Factors of 92 Cases Defined by the Revised European American Lymphoma Classification. Leukemia & lymphoma. 44(2). 241–249. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact